Trial intelligence / Profile preview

N-ICE Trial: Rectal Indomethacin +/- Papillary Ice Water Irrigation for Prevention of Post-ERCP Pancreatitis

NCT07826026Not yet recruiting

Sponsor: Unity Health Toronto
Start: Oct 2026
Primary completion: Oct 2029

Overview

Randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Unity Health Toronto. Primary endpoint: Incidence of Post-ERCP Pancreatitis at 24 hours. Planned start Oct 2026; status: not yet recruiting.

Conditions

post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)

Beyond the preview

Go deeper on NCT07826026.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07826026.